Virus News and Research

Latest Virus News and Research

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Stock-outs of ARV drugs in Central African Republic impact health of HIV-infected people

According to Pierre-Marie David of the University of Montreal's Faculty of Pharmacy, stock-outs of antiretroviral (ARV) drugs in recent years in the Central African Republic have had a dramatic impact on the health of HIV-infected people.

5 Mar 2014

Small-molecule drug effective in protecting nonhuman primates from lethal Marburg virus

For the first time, scientists have demonstrated the effectiveness of a small-molecule drug in protecting nonhuman primates from the lethal Marburg virus. Their work, published online in the journal Nature, is the result of a continuing collaboration between Army scientists and industry partners that also shows promise for treating a broad range of other viral diseases.

5 Mar 2014

New PhoneSoap Charger is most effective way to kill bacteria growing on cell phones

Cell phones have become our constant companions, and as a result, they are exposed to many bacteria and viruses. When we open a door, shake hands, use an ATM or dozens of other daily tasks, our hands come in contact with germs, and numerous studies have shown that a significant number of bacteria, such as the flu virus, staph, strep, E. coli, and salmonella, are transferred from our hands to our cell phones every time we pick them up.

5 Mar 2014

Researchers develop adjuvant which enhances effect of virus transduction

Lentiviruses, which belong to the family of retroviruses, are used as vectors to exchange genetic material in cells and can be used to replace a defective gene as defined by gene therapy.

5 Mar 2014

Novel HIV prevention products for women demonstrate safety in clinical studies

Two early clinical studies of novel HIV prevention products for women - the first combination antiretroviral (ARV) vaginal ring and a vaginal film - show the products to be safe and open the door to product improvements that could expand options for women-initiated prevention tools. The results of both studies were presented today at the 21st Conference on Retroviruses and Opportunistic Infections.

5 Mar 2014

Women using DMPA injection more likely to acquire HIV than women using NET-EN

Women who used an injectable contraceptive called DMPA were more likely to acquire HIV than women using a similar product called NET-EN, according to a secondary analysis of data from a large HIV prevention trial called VOICE, researchers from the National Institutes of Health-funded Microbicide Trials Network reported today at the 21st Conference on Retroviruses and Opportunistic Infections in Boston.

5 Mar 2014

3.5 million estimated Medicaid signups under health law

Avalere Health projects that of the 8.9 million people "determined eligible" for Medicaid starting last Oct. 1, the number of new enrollees under the health law is likely much smaller -- between 2.4 million and 3.5 million. Other reports look at how health insurance could result in nearly half a million more Americans getting tested for HIV by 2017 -- but how 60,000 people with the virus will be left uninsured in states not expanding Medicaid.

5 Mar 2014

Blocking myoferlin gene can reduce breast cancer cell migration

New research suggests that a protein only recently linked to cancer has a significant effect on the risk that breast cancer will spread, and that lowering the protein's level in cell cultures and mice reduces chances for the disease to extend beyond the initial tumor.

4 Mar 2014

Loyola physician sheds light on common and painful viral infection, shingles

Shingles is a painful viral infection that affects almost one million people worldwide and 30 percent of Americans every year.

4 Mar 2014

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Virus News and Research

Latest Virus News and Research

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Stock-outs of ARV drugs in Central African Republic impact health of HIV-infected people

Small-molecule drug effective in protecting nonhuman primates from lethal Marburg virus

New PhoneSoap Charger is most effective way to kill bacteria growing on cell phones

Researchers develop adjuvant which enhances effect of virus transduction

Novel HIV prevention products for women demonstrate safety in clinical studies

Women using DMPA injection more likely to acquire HIV than women using NET-EN

3.5 million estimated Medicaid signups under health law

Blocking myoferlin gene can reduce breast cancer cell migration

Loyola physician sheds light on common and painful viral infection, shingles

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Costly new hepatitis C drug raises questions about who will pay

New findings point the way toward potentially more effective HIV vaccine

First Edition: March 3, 2014

Five women scientists to receive ‘L’Oréal-UNESCO For Women in Science Awards'

Scientists map key elements of immune overreaction triggered by influenza virus infection

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in